Linking shox/shox2 deficiency with fgfr3 gain-of-function and natriuretic peptides
levels, which are reduced by CNP treatment. These results in zebrafish may have implications for other vertebrates, including humans with SHOX deficiency, who should be monitored for cardiac disease in later life, and those who have an inadequate response to growth hormone may profit from CNP therapy.
Authors
- Sabrina Diebold
- Ralph Roeth
- Steffen Just (ORCID: https://orcid.org/0000-0001-7396-1281)
- Annette Löwen
- Gudrun A. Rappold
- Sandra Hoffmann
- Stefanie Mellein
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Institute of Human Genetics (PL)
- German Centre for Cardiovascular Research (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-04-17
- DOI
- https://doi.org/10.3389/fendo.2026.1803846
- Primary Topic
- Developmental Biology and Gene Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00